☆ 4.3 Editorial Material

Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?

EXPERT REVIEW OF ANTICANCER THERAPY (2011)

Get Full Text
Add to Collection

Journal

EXPERT REVIEW OF ANTICANCER THERAPY
Volume 11, Issue 5, Pages 657-660

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.11.44

Keywords

bevacizumab; end points; glioblastoma; overall survival; progression-free survival

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.